421 related articles for article (PubMed ID: 27457511)
1. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
4. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
5. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
6. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
7. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
8. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA
J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961
[TBL] [Abstract][Full Text] [Related]
9. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison.
Wang C; Jing ZC; Huang YG; Zhou DX; Liu ZH; Meier C; Nikkho S; Curram J; Zhang P; He JG
Heart Asia; 2016; 8(1):74-82. PubMed ID: 27326239
[TBL] [Abstract][Full Text] [Related]
11. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
12. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
13. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
[TBL] [Abstract][Full Text] [Related]
14. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
15. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
[TBL] [Abstract][Full Text] [Related]
16. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
18. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
[TBL] [Abstract][Full Text] [Related]
19. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Benza RL; Ghofrani HA; Grünig E; Hoeper MM; Jansa P; Jing ZC; Kim NH; Langleben D; Simonneau G; Wang C; Busse D; Meier C; Ghio S
J Heart Lung Transplant; 2021 Oct; 40(10):1172-1180. PubMed ID: 34353714
[TBL] [Abstract][Full Text] [Related]
20. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
